Comprehensive Snapshot for CRISPR Gene-editing Market Research Report, Including Regional and Country Analysis in Brief.
Industry: Healthcare
Delivery Timelines: Please Contact Sales
Published Date: June-2025
Format: PPT*, PDF, EXCEL
Number of Pages: 187
ID: PMRREP35381
The global CRISPR gene-editing market size is projected to rise from US$ 5.06 Bn in 2025 to US$ 11.02 Bn by 2032. The market is further anticipated to register a CAGR of 11.8% during the forecast period from 2025 to 2032. According to the Persistence Market Research report, growth is driven by the rising demand for CRISPR-based gene-editing for treating genetic illnesses, development of vaccines and novel diagnostic tools, and modifying crops for better yield and quality.
CRISPR gene-editing allows scientists to change an organism's DNA by allowing genetic material to be added, removed, or altered at particular locations in the genome. The well-known gene-editing approach is called CRISPR-Cas9, which is short for clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9. It is faster, cheaper, more accurate, and more efficient than other genome editing methods. As per the Britannica article published in May 2025, CRISPR-Cas9 has been used in editing early embryos and modifying the crop genomes, animals, and bacteriophages to battle antibiotic-resistant bacteria. It has corrected genetic defects in mice and removed HIV from infected cells. These developments highlight the significant growth potential of the market.
Key Industry Highlights
|
Global Market Attribute |
Key Insights: |
|
CRISPR Gene-Editing Market Size (2025E) |
US$ 5.06 Bn |
|
Market Value Forecast (2032F) |
US$ 11.02 Bn |
|
Projected Growth (CAGR 2025 to 2032) |
11.80% |
|
Historical Market Growth (CAGR 2019 to 2024) |
8.00% |
CRISPR technology is transforming medicine through precise genome editing, enabling innovations in genetic disease correction, oncology, regenerative medicine, and infectious disease treatment. The December 2024 study published in Frontiers stated that the advances in CRISPR gene-editing, such as high-fidelity Cas9, base/prime editors, and Cas12/Cas13, have improved accuracy and efficiency. Emerging epigenome editors allow gene regulation without changing DNA, offering safer and reversible treatment options. The FDA approval of the treatment of sickle cell disease using Casgevy highlights its high clinical potential. Recent radical developments highlight CRISPR’s swiftly growing role across diverse fields, fostering its place as a major growth driver in the gene-editing market.
CRISPR gene-editing has been used to repair genetic mutations and combat antibiotic-resistant bacteria. In biomedical research and therapeutics, the interventions by CRISPR are revolutionary. For instance, in May 2025, a U.S. infant with CPS1 deficiency became the first human to receive a personalized gene-editing treatment, marking a significant milestone in rare disease therapeutics. This achievement highlights CRISPR's growing potential in personalized medicine and its capacity to treat rare conditions.
CRISPR-Cas9, a gene-editing tool, enables precise and targeted gene modifications, making it a key technology in Human Germline Engineering (HGE). Ethical concerns about HGE, which modifies embryos or reproductive cells that can pass changes to future generations are hampering market growth. While somatic cell editing (non-heritable) is popular for therapeutic use, germline modifications create moral apprehensions. The nontherapeutic uses of germline genome editing, such as changing physical traits like skin and eye color, which can lead to designer babies with comparable physical and mental features among dissimilar bloodlines.
Another concern is the lack of consent from genome-edited children. According to July 2023 NLM study, gene-editing of the embryo for non-reproduction purposes is allowed in at least 11 countries, including China, the U.S., and the U.K. Nineteen countries, including Belarus, Canada, Sweden, and Switzerland, have banned gene-editing trials on human embryo. Russia has adopted a neutral position.
CRISPR gene-editing also has numerous ecological repercussions. Gene drives to eradicate pests such as mosquitoes could eventually disturb ecosystems. An in-depth study of balancing innovation with ethical responsibility will remain a major step as CRISPR advances to ensure its just application across the realm of medicine and beyond. These bans and regulatory challenges have to be explored considering the benefits and potential risks, so that it can also be responsibly applied to benefit people in dire need.
CRISPR gene-editing allows the precise targeting of specific genes that cause or influence the progression of genetic diseases. As the field evolves and the gene-disease relationships become clearer, gene-editing will help in amending faulty genetic sequences, thereby addressing the root causes of all types of rare and common disorders. Cell therapies, which are already successful in treating diseases such as cancer can be further modified at the genetic level to enhance their safety, efficacy, and accessibility. It is being explored in research and clinical trials for single-gene disorders such as cystic fibrosis, hemophilia, and sickle cell disease. It also holds promise for the treatment and prevention of cancer, heart disease, mental illness, and HIV infection.
CRISPR has the capability to expand the scope and impact of regenerative and precision medicine by creating next-generation cell therapies. Scientists at the University of Bayreuth successfully developed the first CRISPR-Cas9-modified spider capable of producing red fluorescent silk, an innovation published in Angewandte Chemie International Edition (May 2025). This success illustrates CRISPR’s versatility and its potential for use in novel biomaterials and synthetic biology. Such advancements are driving increased investments in research across therapeutic, agricultural, and industrial biotechnology sectors.
By product, the kits & enzymes segment is projected to dominate the CRISPR gene-editing market with an estimated 48% share in 2025, due to their wide-ranging applications in genome modification, gene knockout, and validation studies. According to an NLM 2023 study, CRISPR kits comprise key reagents such as Cas9 enzymes, guide RNAs (gRNAs), and other essential components, offering a pre-optimized solution that streamlines the editing process for researchers. These enzymes, when combined with gRNAs, enable highly accurate DNA editing by targeting specific genetic sequences. According to a May 2024 BMC article, CRISPR-associated enzymes such as Cas9 are widely used to target and correct genetic mutations that drive tumor development and metastasis, highlighting its emerging importance in advancing tumor therapy research and driving the demand.
The libraries segment is anticipated to be the fastest growing segment over the forecast period. DNA Library or Gene Library is a collection of DNA fragments cloned into vectors and stored within host organisms. They contain either the entire genome of a particular organism or the genes that are expressed at a given time. In CRISPR research, libraries refer to collections of guide RNAs (gRNAs) designed to target specific genes within a genome. These libraries are used for high-throughput screening to identify genes involved in specific biological processes or to study how cells respond to various conditions.
The two main types are genomic and cDNA libraries. Genomic libraries help map genomes, study non-coding regions, trace evolutionary relationships, and identify disease-related mutations. cDNA libraries focus on expressed genes, enabling gene cloning, expression profiling, recombinant protein production, and disease gene analysis.
Based on application, the drug discovery & development segment dominates the CRISPR gene-editing market, accounting for a revenue share of approximately 65% in 2025. CRISPR technology supports tailored cancer treatment by exploring patient-specific genetic drivers of tumor growth and resistance. CRISPR-Cas9 helps in the treatment of monogenic diseases, such as sickle cell anemia and β-thalassemia, and has potential in the treatment of Huntington’s and HIV.
CRISPR is also revolutionizing oncology through tailor-made immunotherapy treatments and cancer gene mapping. According to a 2023 Taylor &Francis study, a notable example of CRISPR in action is a trial by PACT Pharma Inc. and the University of California, where scientists edited two T cell receptor genes to reprogram patients’ immune systems to attack their own cancers. Among 16 participants with treatment-resistant cancers, five experienced disease stabilization, demonstrating its potential.
The agriculture segment is projected to be the fast-growing sector as it enables targeted changes in plant DNA to develop crops with desirable traits such as drought tolerance and disease resistance, without adding foreign DNA. According to an article by Innovative Genomics Institute, unlike traditional transgenic methods, CRISPR edits the existing plant genes, thereby faces fewer regulatory hurdles. According to a January 2023 NLM study, CRISPR can modify genes that control the production of certain nutrients, leading to crops with higher levels of vitamins, minerals, or healthy fats. False Flax (Camelina sativa) with enhanced omega-3 oil has been developed using CRISPR technology.
North America is expected to dominate the global CRISPR gene-editing market in 2025, contributing approximately 44% of the total revenue. The well-established R&D centers in North America and increased funding for innovation and clinical trials will drive market growth. The U.S. houses many biotech and pharmaceutical firms and Contract Research Organizations (CROs) including Applied StemCell (ASC), Cellecta, Integrated DNA Technologies (IDT), and Horizon Discovery, which play a pivotal role in supporting these advancements. Favorable regulatory climate that enables innovation and speedy approval of novel therapies also plays a major role in driving market growth.
The CRISPR gene-editing market in the U.S. is expected to account for the largest share in North America in 2025, driven by increasing R&D initiatives and a favorable regulatory environment. In the U.S., gene-edited crops using new breeding techniques such as CRISPR are regulated based on the final product and not the method. This relaxed treatment stems from a 2019 executive order that led to the SECURE Rule, streamlining regulation for low-risk genetically engineered plants. The U.S. government has also made heavy investments in the Precision Medicine Initiative, which offers personalized treatment based on the unique genetic makeup of each person.
The CRISPR gene-editing market in Asia Pacific is expected to grow at the fastest pace during the forecast period, driven by increasing investments in R&D efforts and clinical trials for gene-editing technologies in countries including China and India. The surging chronic and genetic diseases, the growing number of positive clinical trials, and the increased presence of gene therapy-based biotech companies, such as OliX Pharmaceuticals, Souzhou Ribo Life Science, Gennova, Nuevocor, and Abion, also play a major role in attracting huge funding and investments in the field. The rising application of gene-editing technologies in both crop improvement and personalized medicine is a major growth enabler. For instance, Rznomics, founded in South Korea, has five pipeline drugs based on its trans-splicing ribozyme technology to address cancer, neurodegeneration, and genetic eye disorders. One of its products, RZ-001, is already in phase I/IIa trials for treatment of hepatocellular carcinoma and glioblastoma.
China’s gene-editing industry is experiencing significant growth, driven by increasing R&D in gene-editing and the presence of large pharmaceutical conglomerates in China. China has a favorable regulatory environment and policies toward gene-editing, which plays a major role in market growth. An article published in the September 2024 issue of Genetic Engineering and Biotechnology News stated that recent advances in gene therapy, particularly using dual AAV vectors targeting the OTOF gene, have shown promising results in restoring hearing and speech perception in clinical trials in China, including enhanced sound localization and music appreciation.
Europe is experiencing significant growth in the CRISPR-based gene-editing market, driven by strong government support, a collaborative research ecosystem, and proactive regulatory frameworks. Well-established research institutions, active partnerships between academia and the pharmaceutical industry, and substantial funding through initiatives such as Horizon Europe also drive market growth. The European Medicines Agency is increasingly streamlining approval processes for gene-editing therapies, accelerating market entry and innovation. This supportive environment not only fosters advanced R&D but also attracts investment and talent, positioning Europe as a leader in gene-editing.
The U.K. CRISPR-based gene-editing market is projected to witness significant growth, owing to increased government investments in genetic research. Leading universities and research institutions in the U.K. are at the forefront of innovation, supported by strategic partnerships and funding. Editas Medicine, Inc., CRISPR Therapeutics AG, Intellia Therapeutics, Inc. are some of the companies that have secured substantial funding and are involved in various clinical trials related to CRISPR technologies.
The global CRISPR gene-editing market is moderately fragmented, with several key players driving growth through product innovation, strategic partnerships, and acquisitions. Continued investments in R&D to develop new products are expected to strengthen their market position over the forecast period.
|
Report Attribute |
Details |
|
Historical Data/Actuals |
2019 - 2024 |
|
Forecast Period |
2025 - 2032 |
|
Market Analysis |
Value: US$ Bn |
|
Geographical Coverage |
|
|
Segmental Coverage |
|
|
Competitive Analysis |
|
|
Report Highlights |
|
|
Customization and Pricing |
Available upon request |
By Product
By Service
By Application
By Region
To know more about delivery timeline for this report Contact Sales
The global market is projected to be valued at US$ 5.06 Bn in 2025.
The CRISPR gene-editing industry is driven by the rising demand for CRISPR-based gene-editing for treating genetic illnesses, development of vaccines and novel diagnostic tools, and modifying crops for better yield and quality.
The market is poised to witness a CAGR of 11.8% from 2025 to 2032.
R&D efforts are underway to allow the precise targeting of specific genes that cause or influence the progression of genetic diseases.
Major players in the CRISPR gene-editing industry include Revvity, Inc., Danaher, GenScript, Merck KGaA, and Thermo Fisher Scientific, Inc.
